Affiliation:
1. Russian Medical Academy for Continuing Professional Education
2. Moscow State University of Medicine and Dentistry n. a. A. I. Evdokimov
3. Moscow Clinical Scientific and Practical Centre n. a. A. S. Loginov
Abstract
Drug-induced liver injury (DILI) is a fairly frequent adverse drug reaction, which accounts for about half (40–50 %) of cases of acute liver damage. The cholestatic variant of DILI is characterized by an increase in the activity of alkaline phosphatase (ALP) above the two upper limits of the norm (ULN) or the ratio of alanine aminotransferase (ALT) / ALP ≤ 2 in chronic course. A common cause of the cholestatic variant of DILI is a use of drugs for the treatment of infectious diseases, such as beta-lactam antibiotics, Aminoglycosides, Amphenicol, Lincosamides, macrolides, fluoroquinolones, antituberculosis drugs, etc. This problem has acquired particular urgency during the COVID-19 pandemic. The widespread use of azithromycin, hydroxychloroquine, interferons, lopinavir, and other drugs for the treatment of COVID-19 also contributed to an increase in the incidence of DILI. In accordance with clinical guidelines in case of suspicion of a drug-induced liver damage, one should stop use of suspected drug and, if necessary, prescribe hepatoprotectors, for example, ursodeoxycholic acid (UDCA). The effectiveness of the use of UDCA in patients with DILI, including those caused by the intake of antibacterial drugs, has been confirmed by randomized placebo-controlled clinical trials. The effectiveness of UDCA -drug Ursosan® has been confirmed in real life clinical practice. This drug can be used for long-term (up to several months), or lifelong treatment with hepatotoxic drugs like antituberculosis and antirheumatic drugs. The daily dose of Ursosan® is 12–15 mg/kg, if necessary – 20 mg / kg (with a weight of a patient about 75–100 kg, daily dose will be equal to two tablets of Ursosan Forte®, 500 mg).
Subject
Materials Chemistry,Economics and Econometrics,Media Technology,Forestry
Reference83 articles.
1. The official website of the New Zealand Agency for the Safety of Medicines and Health Products Medsafe. Available at: https://www.medsafe.govt.nz/profs/PUArticles/AntibioticsSept2012.htm (accessed 02.26.2021).
2. Ivashkin V. T. Diseases of the liver and biliary tract. A guide for doctors. 2nd ed. V. T. Ivashkin, M.: ID M–Vesti. 2005. 536 p.
3. Ostapowicz G, Fontana RJ, Schiødt FV, Larson A, Davern TJ, Han SH, McCashland TM, Shakil AO, Hay JE, Hynan L, Crippin JS, Blei AT, Samuel G, Reisch J, Lee WM; U. S. Acute Liver Failure Study Group. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002 Dec 17; 137 (12): 947–54. https://doi.org/10.7326/0003–4819–137-12–200212170–00007.
4. Laura Morales M., Natalia Vélez L., Octavio Germán Muñoz M. Hepatotoxicity: A Drug-Induced Cholestatic Pattern. Rev Col Gastroenterol. 2016; 31 (1): 34–45.
5. Fontana RJ, Hayashi PH, Gu J, Reddy KR, Barnhart H, Watkins PB, Serrano J, Lee WM, Chalasani N, Stolz A, Davern T, Talwakar JA; DILIN Network. Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. Gastroenterology. 2014 Jul; 147 (1): 96–108. e4. https://doi.org/10.1053/j.gastro.2014.03.045
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献